Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-1/L1 Inhibitor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT05431569
What this trial is testing

A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer

Who this might be right for
Advanced Lung Cancer
Mabwell (Shanghai) Bioscience Co., Ltd. 36
Not applicableStudy completedNCT02827344
What this trial is testing

PDL-1 Expression on Circulating Tumor Cells in Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer
University Hospital, Toulouse 216
Early research (Phase 1)Looking for participantsNCT05911464
What this trial is testing

A Phase I Study of HS-10386 in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
Jiangsu Hansoh Pharmaceutical Co., Ltd. 248
Not applicableLooking for participantsNCT06693440
What this trial is testing

The Immune Assessment of PD-1 Antibody Therapy in Tumor

Who this might be right for
Efficacy, TeamAdverse Event
Quanli Gao 3,000
Large-scale testing (Phase 3)Ended earlyNCT03729245
What this trial is testing

Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)

Who this might be right for
Renal Cell CarcinomaMetastatic Renal Cell Carcinoma
Nektar Therapeutics 623
Testing effectiveness (Phase 2)Study completedNCT02404441
What this trial is testing

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Who this might be right for
MelanomaNon-small Sell Lung Cancer (NSCLC)Triple Negative Breast Cancer+2 more
Novartis Pharmaceuticals 319
Not applicableStudy completedNCT03387540
What this trial is testing

Evaluation of Reporting of Immune Checkpoint Inhibitor Associated Cardio-vascular Adverse Reactions

Who this might be right for
MyocarditisCardiac Complication
Groupe Hospitalier Pitie-Salpetriere 104
Testing effectiveness (Phase 2)Study completedNCT02579811
What this trial is testing

Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer

Who this might be right for
Metastatic Renal Cell Cancer
Case Comprehensive Cancer Center 40
Testing effectiveness (Phase 2)Study completedNCT02694822
What this trial is testing

AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy

Who this might be right for
Advanced Solid CancersAdvanced Solid Cancers Refractory to PD-1 and PD-L1 Therapies
Agenus Inc. 89
Early research (Phase 1)Study completedNCT04130763
What this trial is testing

Fecal Microbiota Transplant (FMT) Capsule for Improving the Efficacy of Anti- PD-1

Who this might be right for
Gastrointestinal System Cancer
Peking University 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT04831320
What this trial is testing

Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor

Who this might be right for
Metastatic Head-and-neck Squamous-cell Carcinoma
Washington University School of Medicine 46
Testing effectiveness (Phase 2)UnknownNCT05401279
What this trial is testing

Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer

Who this might be right for
Urothelial Carcinoma BladderPD-1 Inhibitor
RenJi Hospital 20
Testing effectiveness (Phase 2)UnknownNCT06586697
What this trial is testing

First-line Treatment for ES-SCLC with Chemotherapy Combined with PD-1/PD-L1 Inhibitor Sequential Thoracic Radiotherapy

Who this might be right for
Extensive-stage Small-cell Lung Cancer
Henan Cancer Hospital 47
Testing effectiveness (Phase 2)Ended earlyNCT03637803
What this trial is testing

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

Who this might be right for
OncologySolid TumorNon Small Cell Lung Cancer+3 more
4D pharma plc 63
Testing effectiveness (Phase 2)Looking for participantsNCT07312422
What this trial is testing

LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study

Who this might be right for
Pancreatic CancerPD-L1PD-1 Inhibitor+2 more
Zhejiang Provincial People's Hospital 10
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07230314
What this trial is testing

Sequential Transarterial Chemoembolization (TACE), Stereotactic Body Radiation Therapy (SBRT), and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma Treated With Donafenib

Who this might be right for
Unresectable Hepatocellular Carcinoma
Jinling Hospital, China 34
Large-scale testing (Phase 3)Not Yet RecruitingNCT07797153
What this trial is testing

JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer

Who this might be right for
Recurrent or Metastatic Cervical Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd 368
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06028633
What this trial is testing

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

Who this might be right for
Advanced Non-squamous Non-small-cell Lung CancerRecurrent Non-Squamous Non-Small Cell Lung CancerMetastatic Non-squamous Non Small Cell Lung Cancer
Peking University First Hospital 28
Testing effectiveness (Phase 2)UnknownNCT05325684
What this trial is testing

PD-L1 Inhibitor Rechallenge After PD-1 Immunotherapy for Patients With Solid Tumor Beyond Lung Cancer

Who this might be right for
EfficacySafety
The Affiliated Hospital of Qingdao University 30
Testing effectiveness (Phase 2)WithdrawnNCT05022394
What this trial is testing

Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study

Who this might be right for
Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage I Lung Cancer AJCC v8+10 more
M.D. Anderson Cancer Center
Next Page